Drug Trial Radar · NCT01439360
An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
Last checked: Nov 19, 2026Latest source record: Sep 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,046
Actual
Start
Oct 1, 2011
Primary completion
Oct 31, 2014
Study completion Dec 31, 2014
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 months, up to 35 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of GSK Biologicals' influenza candidate vaccine GSK2321138A when compared to non-influenza vaccine comparators in children 6 to 35 months of age. Recruitment will encompass at least 4 independent cohorts: a first cohort in the Northern Hemisphere (2011-2012), a second cohort in subtropical countries (2012), third cohort in the Northern Hemisphere (2012-2013) and a fourth cohort and additional independent cohorts possibly in NH countries (end 2013) and subtropical countries (beginning 2014).
Conditions
- Influenza
Interventions
Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138ABiological
Intramuscular injection
Havrix JuniorBiological
Intramuscular injection administered to subjects aged 12 months or older
Prevenar 13Biological
Intramuscular injection administered to subjects less than 12 months of age
Varivax/ProVarivaxBiological
Intramuscular injection administered to subjects more than 12 months of age
VarilrixBiological
Subcutaneous injection administered to subjects more than 12 months of age
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Moderate to Severe RT-PCR Confirmed Influenza.Time frame: During the surveillance period (approximately 6 to 8 months)
- Number of Subjects With RT-PCR Confirmed Influenza of Any Severity.Time frame: During the surveillance period (approximately 6 to 8 months)
Locations
103 sites in 13 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Dhaka, Bangladesh
GSK Investigational Site
Antwerp, Belgium
GSK Investigational Site
Antwerp, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Mechelen, Belgium
GSK Investigational Site
Namur, Belgium
GSK Investigational Site
Roeselaere, Belgium
GSK Investigational Site
Turnhout, Belgium
GSK Investigational Site
Děčín, Czechia
GSK Investigational Site
Humpolec, Czechia
GSK Investigational Site
Jindřichův Hradec, Czechia
GSK Investigational Site
Liberec, Czechia
GSK Investigational Site
Lipník nad Bečvou, Czechia
GSK Investigational Site
Náchod, Czechia
GSK Investigational Site
Odolena Voda, Czechia
GSK Investigational Site
Ostrava - Poruba, Czechia
GSK Investigational Site
Pardubice, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Tábor, Czechia
GSK Investigational Site
Santo Domingo, Dominican Republic
GSK Investigational Site
Santo Domingo, Distrito Nacional, Dominican Republic
GSK Investigational Site
San Pedro Sula, Honduras
GSK Investigational Site
Tegucigalpa, Honduras
GSK Investigational Site
Faridabad, India
GSK Investigational Site
Pune, India
GSK Investigational Site
Pune, India
GSK Investigational Site
Beirut, Lebanon
GSK Investigational Site
City of Muntinlupa, Philippines
GSK Investigational Site
Manila, Philippines
GSK Investigational Site
Manila, Philippines
GSK Investigational Site
Metro Manila, Philippines
GSK Investigational Site
Quezon City, Philippines
GSK Investigational Site
Sampaloc, Manila, Philippines
GSK Investigational Site
Bydgoszcz, Poland
GSK Investigational Site
Bydgoszcz, Poland
GSK Investigational Site
Bydgoszcz, Poland
GSK Investigational Site
Dębica, Poland
GSK Investigational Site
Gdansk, Poland
GSK Investigational Site
Grudziądz, Poland
GSK Investigational Site
Katowice, Poland
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.